Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.

9571Background: PD-L1 expression on tumors contributes to tumor escape from immune surveillance. In order to determine whether PD-L1 might be useful to identify those patients (pts) with melanoma m...